Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/49964
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBlumental, Sophie-
dc.contributor.authorLAJOT, Adrien-
dc.contributor.authorVandromme, Mathil-
dc.contributor.authorLafort, Yves-
dc.contributor.authorDOCKX, Yinthe-
dc.contributor.authorDenayer, Sarah-
dc.contributor.authorWampers, Alicia-
dc.contributor.authorNebbioso, Andrea-
dc.contributor.authorTilmanne, Anne-
dc.contributor.authorMignon, Celine-
dc.contributor.authorTuerlinckx, David-
dc.contributor.authorRigolle, Hanne-
dc.contributor.authorMatthijs, Inge-
dc.contributor.authorVandersnickt, Jan-
dc.contributor.authorHellinckx, Johan-
dc.contributor.authorDewulf, Jonas-
dc.contributor.authorCoppens, Katrien-
dc.contributor.authorVan Hoorenbeeck, Kim-
dc.contributor.authorVanlede, Koen-
dc.contributor.authorWinters, Lore-
dc.contributor.authorSeyler, Lucie-
dc.contributor.authorParsy, Marie-Pierre-
dc.contributor.authorReynders , Marijke-
dc.contributor.authorBalcaen, Mathilde-
dc.contributor.authorUrbina, Montse-
dc.contributor.authorDauby, Nicolas-
dc.contributor.authorChatzis, Olga-
dc.contributor.authorNaesens, Reinout-
dc.contributor.authorDorval, Sarah-
dc.contributor.authorTernest, Silke-
dc.contributor.authorVanspeybroeck, Sophie-
dc.contributor.authorGoetghebuer, Tessa-
dc.contributor.authorVan Ackere, Tine-
dc.contributor.authorSelimaj Kontoni, Valbona-
dc.contributor.authorEl Bitar, Wassim-
dc.contributor.authorHolemans, Xavier-
dc.contributor.authorBruyere, Yveline-
dc.contributor.authorVan Brusselen, Daan-
dc.contributor.authorDe Mot, Laurane-
dc.contributor.authorRAES, Marc-
dc.date.accessioned2026-09-02T06:55:21Z-
dc.date.available2026-09-02T06:55:21Z-
dc.date.issued2026-
dc.date.submitted2026-09-02T06:43:37Z-
dc.identifier.citationBMC Infectious Diseases, 26 (1) (Art N° 1494)-
dc.identifier.urihttp://hdl.handle.net/1942/49964-
dc.description.abstractBackground Since 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024-2025, nirsevimab started to be administered in Belgium to infants < 6 months old encountering their first RSV season. We aim to evaluate on a national scale the impact of RSV prevention in the pediatric hospital setting. Method This survey pooled data from two surveillance systems: the prospective SARI (Severe Acute Respiratory Infection) surveillance (6 hospitals) and the retrospective RSVPed study (25 hospitals). Both used the same case definition and clinical questionnaire to record RSV hospitalizations in children < 5 years. Seasonal incidences and clinical data were compared between seasons 2023-2024 (pre-prevention) and 2024-2025 (first year of prevention). Results Our study covered 47% of all pediatric beds in Belgium. We demonstrated a reduction of 39% in pediatric RSV-related hospitalizations and of 57% in RSV-related admissions to intensive care units during 2024-2025 compared to 2023-2024. Incidences decline mainly concerned infants < 6 months, without changes in older age groups. Furthermore, savings in health care resources were observed through shorter length of stay and significantly less use of non-invasive ventilatory support and nutritional support among hospitalized cases in 2024-2025. Conclusion Following implementation of nirsevimab, a substantial reduction in RSV paediatric burden was observed in Belgium. However, efforts should be made to increase the uptake of preventive tools in our country to achieve better effectiveness. This study also highlights the major role of a national network to monitor efficacy of prevention over time.Clinical trial number Not applicable.-
dc.description.sponsorshipFunding The RSVPed study has received a support from the Care Foundation, Chirec, Brussels, Belgium (research grant for the first year of the survey). The national SARI surveillance is funded by the Belgian Federal Public Service ‘Health, Food Chain Safety, and Environment’ and is also part of the VEBIS (Vaccine Effectiveness, Burden and Impact Studies) project funded by the European Centre for Disease Prevention and Control (Framework Contract ECDC/2021/016); European Union (BE-SURVID project). Acknowledgements We thank Danielle Strens for her precious help in collecting many data for the RSVPED survey and managing administrative procedures. We thank Hilde Kelchtermans for her help in managing administrative queries and filling in procedures for ethical committees’ approval. We thank Dominique Grossman for her support in setting up the study and in obtaining funding for the first year of survey. We thank Anna Parys and François Dufrasne from the National Reference Centre of Respiratory Pathogens for their contributions to samples analysis. We are grateful to Nathalie Bossuyt and Koen Blot for their precious support, especially when setting up the study. We thank Sven Hanoteaux for his input in data analysis. We thank Amaury Delestienne, Alexandra Van Heyck, Julie Frère, Catherine Sondag, Gabriella Kollár, Sigi Van Den Wijngaert, Benedicte Mondovits, Arne Witdouck, Siel Daelemans, Silvana Sokolji, Sandrine Roisin, Delphine Le Paige, Anne Sophie Bouteiller, Muriel Van Vaerenbergh, Ingrid Thomas, Sandra Koenig, Diane Stroobant, Marc Bourgeois, Koen Magerman and Typhaine Corbisier for their precious contribution in data or samples collection. We are grateful to Mark Wojciechowski for his proofreading of our article. We thank all participants of the BELSARI-NET research group for their contribution to the SARI surveillance (BELSARI-NET research group | sciensano.be).-
dc.language.isoen-
dc.publisherBMC-
dc.rightsThe Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creati vecommons.org/licenses/by-nc-nd/4.0/.-
dc.subject.otherBronchiolitis-
dc.subject.otherMonoclonals-
dc.subject.otherPrevention-
dc.subject.otherImmunization-
dc.subject.otherSurvey-
dc.subject.otherRSV-
dc.subject.otherNirsevimab-
dc.titleNational real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium-
dc.typeJournal Contribution-
dc.identifier.issue1-
dc.identifier.volume26-
local.format.pages12-
local.bibliographicCitation.jcatA1-
dc.description.notesBlumental, S (corresponding author), Delta Hosp, Chirec Hosp Grp, Intens Care Dept, Brussels, Belgium.; Blumental, S (corresponding author), Univ libre Bruxelles, Brussels Univ Hosp, Acad Children Hosp Queen Fabiola, Nutr & Metab Clin, Brussels, Belgium.; De Mot, L (corresponding author), Epidemiol Infect Dis, Sciensano, B-1050 Brussels, Belgium.-
dc.description.notessophie.blumental@ulb.be; adrien.lajot@sciensano.be;-
dc.description.notesmathil.vandromme@sciensano.be; yves.lafort@sciensano.be;-
dc.description.notesyinthe.dockx@sciensano.be; sarah.denayer@sciensano.be;-
dc.description.notesaliciawampers@hotmail.com; andreanebbioso@protonmail.com;-
dc.description.notesanne.tilmanne@ulb.be; celine.mignon@hubruxelles.be;-
dc.description.notesdavid.tuerlinckx@chuuclnamur.uclouvain.be;-
dc.description.noteshanne.rigolle@ziekenhuiswaregem.be; inge.matthijs@azdelta.be;-
dc.description.notesjan.vandersnickt@azturnhout.be; johan.hellinckx@klina.be;-
dc.description.notesjonas.dewulf@azgroeninge.be; katrien.coppens@imelda.be;-
dc.description.noteskim.vanhoorenbeeck@uza.be; koen.vanlede@vitaz.be;-
dc.description.noteslore.winters@azdiest.be; lucie.seyler@uzbrussel.be;-
dc.description.notesmarie-pierre.parsy@chwapi.be; marijke.reynders@azsintjan.be;-
dc.description.notesmathilde.balcaen@saintluc.uclouvain.be; montse.urbina@intermut.be;-
dc.description.notesnicolas.dauby@stpierre-bru.be; olga.chatzis@saintluc.uclouvain.be;-
dc.description.notesreinout.naesens@zas.be; sarah.dorval@chc.be; silke.ternest@uzgent.be;-
dc.description.notessophie.vanspeybroeck@gmail.com; tessa.goetghebuer@stpierre-bru.be;-
dc.description.notest_vanackere@hotmail.com; vselimaj@clstjean.be; wassim.elbitar@chirec.be;-
dc.description.notesxavier.holemans@ghdc.be; yveline.bruyere@humani.be;-
dc.description.notesdaan.vanbrusselen@zas.be; laurane.demot@sciensano.be; raesm044@gmail.com-
local.publisher.placeCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr1494-
dc.identifier.doi10.1186/s12879-026-13419-y-
dc.identifier.pmid42163123-
dc.identifier.isi001849388100001-
dc.contributor.orcidDewulf, Jonas/0000-0003-4760-4074-
local.provider.typewosris-
local.description.affiliation[Blumental, Sophie] Delta Hosp, Chirec Hosp Grp, Intens Care Dept, Brussels, Belgium.-
local.description.affiliation[Blumental, Sophie] Univ libre Bruxelles, Brussels Univ Hosp, Acad Children Hosp Queen Fabiola, Nutr & Metab Clin, Brussels, Belgium.-
local.description.affiliation[Lajot, Adrien; Vandromme, Mathil; Lafort, Yves; Dockx, Yinthe; De Mot, Laurane] Epidemiol Infect Dis, Sciensano, B-1050 Brussels, Belgium.-
local.description.affiliation[Denayer, Sarah] Sciensano, Natl Influenza Ctr, Brussels, Belgium.-
local.description.affiliation[Wampers, Alicia] Algemeen Ziekenhuis Sint Maria Halle, Dept Nephrol, Halle, Belgium.-
local.description.affiliation[Nebbioso, Andrea] Iris Hosp South, Dept Orthoped, Brussels, Belgium.-
local.description.affiliation[Tilmanne, Anne] CHU Tivoli, Dept Gastroenterol, B-7100 La Louviere, Belgium.-
local.description.affiliation[Tilmanne, Anne; Bruyere, Yveline] Hop Civil Marie Curie, Gastroenterol Dept, Charleroi, Belgium.-
local.description.affiliation[Tilmanne, Anne; Goetghebuer, Tessa] Univ Libre Bruxelles, Fac Med, Brussels, Belgium.-
local.description.affiliation[Mignon, Celine] Univ Libre Bruxelles, Brussels Univ Hosp, Acad Children Hosp Queen Fabiola, Dept Paediat,Infect Dis Unit, Brussels, Belgium.-
local.description.affiliation[Tuerlinckx, David] UCLouvain, Dept Intens Care, CHU UCL Namur Dinant S, Dinant, Belgium.-
local.description.affiliation[Rigolle, Hanne] OLV van Lourdes Ziekenhuis Waregem, Dept Paediat, Waregem, Belgium.-
local.description.affiliation[Matthijs, Inge] Algemeen Ziekenhuis Delta, Dept Cardiol, Roeselare, Belgium.-
local.description.affiliation[Vandersnickt, Jan] Algemeen Ziekenhuis Turnhout, Dept Paediat, Turnhout, Belgium.-
local.description.affiliation[Hellinckx, Johan] Algemeen Ziekenhuis Klina, Dept Obstet & Gynaecol, Brasschaat, Belgium.-
local.description.affiliation[Dewulf, Jonas] Algemeen Ziekenhuis Groeninge, Dept Nephrol, Kortrijk, Belgium.-
local.description.affiliation[Coppens, Katrien] Radiol Dept, Imeldaziekenhuis, Bonheiden, Belgium.-
local.description.affiliation[Van Hoorenbeeck, Kim] Antwerp Univ Hosp, Dept Paediat, Edegem, Belgium.-
local.description.affiliation[Van Hoorenbeeck, Kim] Univ Antwerp, Lab Expt Med & Paediat, Antwerp, Belgium.-
local.description.affiliation[Vanlede, Koen] Vitaz, Dept Gastroenterol & Hepatol, St Niklaas, Belgium.-
local.description.affiliation[Winters, Lore] Algemeen Ziekenhuis Diest, Dept Urol, Diest, Belgium.-
local.description.affiliation[Seyler, Lucie] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Internal Med & Infectiol, Vital Res Grp MIPI, Brussels, Belgium.-
local.description.affiliation[Parsy, Marie-Pierre] Ctr Hospitalier Wallonie Picarde, Maxillofacial Surg Dept, Tournai, Belgium.-
local.description.affiliation[Reynders, Marijke] Algemeen Ziekenhuis Sint Jan Brugge Oostende, Dept Lab Med, B-8000 Brugge, Belgium.-
local.description.affiliation[Balcaen, Mathilde] Catholic Univ Louvain, St Luc Univ Hosp, B-1200 Brussels, Belgium.-
local.description.affiliation[Urbina, Montse] IMA AIM, Intermutualist Agentschap Agence Intermutualiste, Brussels, Belgium.-
local.description.affiliation[Dauby, Nicolas] Univ Libre Bruxelles, Dept Infect Dis, CHU St Pierre, Brussels, Belgium.-
local.description.affiliation[Dauby, Nicolas] Univ Libre Bruxelles, Sch Publ Hlth, Brussels, Belgium.-
local.description.affiliation[Chatzis, Olga] Catholic Univ Louvain, St Luc Univ Hosp, Dept Neurol, B-1200 Brussels, Belgium.-
local.description.affiliation[Naesens, Reinout] Ziekenhuis Stroom ZAS, Dept Pathol, Antwerp, Belgium.-
local.description.affiliation[Dorval, Sarah] CHC MontLegia, Dept Neurol, Comprehens Stroke Unit, Liege, Belgium.-
local.description.affiliation[Ternest, Silke] Ghent Univ Hosp, Dept Infect Control, Ghent, Belgium.-
local.description.affiliation[Vanspeybroeck, Sophie] Algemeen Ziekenhuis AZ Jan Palfijn Gent, Dept Immunol & Allergol, Ghent, Belgium.-
local.description.affiliation[Goetghebuer, Tessa] Univ Libre Bruxelles, Dept Paediat, CHU St Pierre, Brussels, Belgium.-
local.description.affiliation[Van Ackere, Tine] Jan Yperman Ziekenhuis, Dept Cardiol, Ypres, Belgium.-
local.description.affiliation[Selimaj Kontoni, Valbona] Clin St Jean, Dept Pathol, Brussels, Belgium.-
local.description.affiliation[El Bitar, Wassim] CHIREC Sainte Anne St Remi Clin, Dept Anesthesiol, Brussels, Belgium.-
local.description.affiliation[Holemans, Xavier] Grand Hop Charleroi, Dept Infect Dis, Charleroi, Belgium.-
local.description.affiliation[Van Brusselen, Daan] Ziekenhuis Stroom ZAS, Dept Pathol, PA2, Antwerp, Belgium.-
local.description.affiliation[Van Brusselen, Daan] Univ Antwerp, Paediat Clin Trial Network, Antwerp, Belgium.-
local.description.affiliation[Raes, Marc] Jessa Ziekenhuis, Dept Hematol, Hasselt, Belgium.-
local.uhasselt.internationalno-
item.contributorBlumental, Sophie-
item.contributorLAJOT, Adrien-
item.contributorVandromme, Mathil-
item.contributorLafort, Yves-
item.contributorDOCKX, Yinthe-
item.contributorDenayer, Sarah-
item.contributorWampers, Alicia-
item.contributorNebbioso, Andrea-
item.contributorTilmanne, Anne-
item.contributorMignon, Celine-
item.contributorTuerlinckx, David-
item.contributorRigolle, Hanne-
item.contributorMatthijs, Inge-
item.contributorVandersnickt, Jan-
item.contributorHellinckx, Johan-
item.contributorDewulf, Jonas-
item.contributorCoppens, Katrien-
item.contributorVan Hoorenbeeck, Kim-
item.contributorVanlede, Koen-
item.contributorWinters, Lore-
item.contributorSeyler, Lucie-
item.contributorParsy, Marie-Pierre-
item.contributorReynders , Marijke-
item.contributorBalcaen, Mathilde-
item.contributorUrbina, Montse-
item.contributorDauby, Nicolas-
item.contributorChatzis, Olga-
item.contributorNaesens, Reinout-
item.contributorDorval, Sarah-
item.contributorTernest, Silke-
item.contributorVanspeybroeck, Sophie-
item.contributorGoetghebuer, Tessa-
item.contributorVan Ackere, Tine-
item.contributorSelimaj Kontoni, Valbona-
item.contributorEl Bitar, Wassim-
item.contributorHolemans, Xavier-
item.contributorBruyere, Yveline-
item.contributorVan Brusselen, Daan-
item.contributorDe Mot, Laurane-
item.contributorRAES, Marc-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.fullcitationBlumental, Sophie; LAJOT, Adrien; Vandromme, Mathil; Lafort, Yves; DOCKX, Yinthe; Denayer, Sarah; Wampers, Alicia; Nebbioso, Andrea; Tilmanne, Anne; Mignon, Celine; Tuerlinckx, David; Rigolle, Hanne; Matthijs, Inge; Vandersnickt, Jan; Hellinckx, Johan; Dewulf, Jonas; Coppens, Katrien; Van Hoorenbeeck, Kim; Vanlede, Koen; Winters, Lore; Seyler, Lucie; Parsy, Marie-Pierre; Reynders , Marijke; Balcaen, Mathilde; Urbina, Montse; Dauby, Nicolas; Chatzis, Olga; Naesens, Reinout; Dorval, Sarah; Ternest, Silke; Vanspeybroeck, Sophie; Goetghebuer, Tessa; Van Ackere, Tine; Selimaj Kontoni, Valbona; El Bitar, Wassim; Holemans, Xavier; Bruyere, Yveline; Van Brusselen, Daan; De Mot, Laurane & RAES, Marc (2026) National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium. In: BMC Infectious Diseases, 26 (1) (Art N° 1494).-
crisitem.journal.eissn1471-2334-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
s12879-026-13419-y.pdfPublished version2.09 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.